Novo Nordisk A/S - Stock

Novo Nordisk A/S ROA 2024

Novo Nordisk A/S ROA








In 2024, Novo Nordisk A/S's return on assets (ROA) was 0.27, a 15.62% increase from the 0.23 ROA in the previous year.

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. It was founded in 1923 and has its headquarters in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the key players in the field of diabetes treatment. Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf

ROA Details

Understanding Novo Nordisk A/S's Return on Assets (ROA)

Novo Nordisk A/S's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Novo Nordisk A/S's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Novo Nordisk A/S's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Novo Nordisk A/S’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Novo Nordisk A/S Stock

What is the Return on Assets (ROA) of Novo Nordisk A/S this year?

The Return on Assets (ROA) of Novo Nordisk A/S is 0.27 undefined this year.

What was the ROA of Novo Nordisk A/S compared to the previous year?

The ROA of Novo Nordisk A/S has increased by 15.62% compared to the previous year.

What consequences do high ROA have for investors of Novo Nordisk A/S?

A high ROA is advantageous for investors of Novo Nordisk A/S, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Novo Nordisk A/S?

A low ROA can be unfavorable for investors of Novo Nordisk A/S as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Novo Nordisk A/S affect the company?

An increase in ROA of Novo Nordisk A/S can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Novo Nordisk A/S impact the company?

A reduction in the ROA of Novo Nordisk A/S can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Novo Nordisk A/S?

Some factors that can influence the ROA of Novo Nordisk A/S include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Novo Nordisk A/S important for investors?

The ROA of Novo Nordisk A/S is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Novo Nordisk A/S take to improve ROA?

To improve ROA, Novo Nordisk A/S can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.44 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.44 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.52 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 3/26/2024 amounting to 6.4 DKK, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.